Related Experiment Video
Updated: Apr 10, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Insights
Betablockers remain vital in cardiology for hypertension and heart failure. However, recent analyses question their established role, prompting a review of current evidence and potential guideline changes.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Betablockers are a cornerstone in cardiovascular medicine, widely used for arterial hypertension, post-myocardial infarction secondary prevention, and heart failure with reduced ejection fraction.
- Recent studies and analyses have introduced controversies, challenging the previously unquestioned efficacy and role of betablockers in specific cardiovascular conditions.
Purpose of the Study:
- To review and summarize the accumulated controversies surrounding the use of betablockers in key cardiovascular indications.
- To analyze the impact of these controversies on current clinical practice guidelines and predict future modifications.
Main Methods:
- Systematic review of recent analyses and published information regarding betablocker use in cardiovascular medicine.
- Focus on controversies in hypertension, secondary prevention of coronary artery disease, perioperative care, and heart failure treatment.
Main Results:
- Significant controversies have emerged regarding the established indications for betablockers.
- Some controversies have already influenced modifications in clinical practice guidelines.
- Further guideline changes are anticipated in the near future based on ongoing research and debate.
Conclusions:
- The role of betablockers in certain cardiovascular conditions is under re-evaluation.
- Evidence-based controversies are driving changes in treatment guidelines for arterial hypertension, secondary prevention, perioperative care, and heart failure.
- Clinicians and researchers must stay abreast of evolving recommendations for optimal patient care.
Abstract:
Betablockers are one of the most successful drug classes in cardiology. They have many indications - starting with treatment of arterial hypertension, continuing with secondary prevention post myocardial infarction up to the treatment of heart failure with reduced ejection fraction. Recently, many analysis and information were published which are questioning yet unshakable role of betablockers in some cardiovascular diagnosis. This review article summarizes the controversies, which have accumulated around betablockers in the treatment of hypertension, secondary prevention of coronary artery disease, perioperative administration in patients undegoing non-cardiac surgery and treatment of heart failure with reduced ejection fraction. Some of these controversies already led to guidelines modifications, other will probably lead to guidelines changes in near future.Key words: arterial hypertension - betablockers - heart failure - perioperative care - secondary prevention.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Action of β1 Blockers
